Opus Genetics, Inc. (NASDAQ:IRD) CEO Purchases $98,000.00 in Stock

Opus Genetics, Inc. (NASDAQ:IRD) CEO George Magrath bought 100,000 shares of the stock in a transaction that occurred on Thursday, December 26th. The shares were bought at an average cost of $0.98 per share, with a total value of $98,000.00. Following the completion of the purchase, the chief executive officer now directly owns 599,150 shares in the company, valued at $587,167. This represents a 20.03 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

George Magrath also recently made the following trade(s):

• On Monday, November 18th, George Magrath acquired 9,706 shares of Opus Genetics stock. The shares were bought at an average cost of $1.02 per share, with a total value of $9,900.12.
• On Friday, November 15th, George Magrath purchased 90,294 shares of Opus Genetics stock. The stock was purchased at an average price of $1.01 per share, with a total value of $91,196.94.

Opus Genetics Stock Up 6.2 %

Shares of NASDAQ IRD opened at $1.19 on Thursday. Opus Genetics, Inc. has a 1 year low of $0.81 and a 1 year high of $3.40. The stock has a market cap of $37.57 million, a price-to-earnings ratio of -1.09 and a beta of 0.19.

Opus Genetics (NASDAQ:IRD) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.01. Opus Genetics had a negative return on equity of 63.65% and a negative net margin of 324.45%. The firm had revenue of $3.87 million during the quarter, compared to the consensus estimate of $1.17 million. On average, equities research analysts expect that Opus Genetics, Inc. will post -1.22 EPS for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of Opus Genetics in a report on Thursday, December 12th.

Opus Genetics Company Profile

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.